Bellevue Group AG
Q4 2021 13F-HR Holdings
Net value change ($000)
-152,476
(-1.5%)
New positions
14
Sold out positions
42
Turnover %
1.3%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q3 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ABT | 81,799 | 49.9% |
| VRTX | 73,931 | 23.1% |
| CDNA | 64,738 | 3301.3% |
| DHR | 55,677 | 40.0% |
| MOH | 54,413 | 119.2% |
| ARGX | 52,004 | 17.5% |
| Intra-Cellular Therapies, Inc. | 49,247 | 35.0% |
| KZR | 43,065 | 110.0% |
| ADY | 34,175 | 75.7% |
| ELV | 33,889 | 19.1% |
Top Reduces (Value $000, Stocks/ETFs)
| MRNA | -230,672 | -34.7% |
| HRC | -63,107 | -100.0% |
| AGIO | -57,422 | -28.7% |
| Radius Health, Inc. | -42,650 | -44.2% |
| MGNX | -41,528 | -23.2% |
| ALNY | -39,511 | -14.9% |
| BAX | -35,640 | -48.0% |
| CRSP | -35,235 | -32.3% |
| GBIO | -34,561 | -55.8% |
| Myovant Sciences Ltd. | -33,406 | -25.8% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|